Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reduced SARS-COV-2 infection and death after two doses of COViD-19 vaccines in a series of 1503 cancer patients.

Literature DB >> 34333128

Reduced SARS-COV-2 infection and death after two doses of COViD-19 vaccines in a series of 1503 cancer patients.

P Heudel¹, B Favier², S Assaad¹, P Zrounba³, J-Y Blay⁴.

Abstract

Entities: Disease Gene Species

Year: 2021 PMID： 34333128 PMCID： PMC8321960 DOI： 10.1016/j.annonc.2021.07.012

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

× No keyword cloud information.

5 in total

1. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

Authors: Lindsey E Roeker; David A Knorr; Meghan C Thompson; Mariely Nivar; Sonia Lebowitz; Nicole Peters; Isaac Deonarine; Saddia Momotaj; Saumya Sharan; Vanessa Chanlatte; Bianca Hampton; Liana Butala; Lindsay Amato; Angela Richford; Jessica Lunkenheimer; Kristen Battiato; Carissa Laudati; Anthony R Mato
Journal: Leukemia Date: 2021-05-13 Impact factor: 11.528

2. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19.

Authors: M L Solodky; C Galvez; B Russias; P Detourbet; V N'Guyen-Bonin; A-L Herr; P Zrounba; J-Y Blay
Journal: Ann Oncol Date: 2020-05-01 Impact factor: 32.976

3. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.

Authors: J Barrière; E Chamorey; Z Adjtoutah; O Castelnau; A Mahamat; S Marco; E Petit; A Leysalle; V Raimondi; M Carles
Journal: Ann Oncol Date: 2021-04-28 Impact factor: 32.976

4. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Authors: Leticia Monin; Adam G Laing; Miguel Muñoz-Ruiz; Duncan R McKenzie; Irene Del Molino Del Barrio; Thanussuyah Alaguthurai; Clara Domingo-Vila; Thomas S Hayday; Carl Graham; Jeffrey Seow; Sultan Abdul-Jawad; Shraddha Kamdar; Elizabeth Harvey-Jones; Rosalind Graham; Jack Cooper; Muhammad Khan; Jennifer Vidler; Helen Kakkassery; Shubhankar Sinha; Richard Davis; Liane Dupont; Isaac Francos Quijorna; Charlotte O'Brien-Gore; Puay Ling Lee; Josephine Eum; Maria Conde Poole; Magdalene Joseph; Daniel Davies; Yin Wu; Angela Swampillai; Bernard V North; Ana Montes; Mark Harries; Anne Rigg; James Spicer; Michael H Malim; Paul Fields; Piers Patten; Francesca Di Rosa; Sophie Papa; Timothy Tree; Katie J Doores; Adrian C Hayday; Sheeba Irshad
Journal: Lancet Oncol Date: 2021-04-27 Impact factor: 41.316

5. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.

Authors: Souad Assaad; Virginie Avrillon; Marie-Line Fournier; Benedicte Mastroianni; Bruno Russias; Aurélie Swalduz; Philippe Cassier; Lauriane Eberst; Marie-Pierre Steineur; Marianne Kazes; Maurice Perol; Anne-Sophie Michallet; Philippe Rey; Anne-Sophie Erena-Penet; Astrid Morel; Mehdi Brahmi; Armelle Dufresne; Olivier Tredan; Gisèle Chvetzoff; Jérome Fayette; Christelle de la Fouchardiere; Isabelle Ray-Coquard; Thomas Bachelot; Pierre Saintigny; Mayeul Tabutin; Aurélien Dupré; Emmanuelle Nicolas-Virelizier; Amine Belhabri; Pierre-Eric Roux; Christine Fuhrmann; Franck Pilleul; Alexandre Basle; Amine Bouhamama; Christelle Galvez; Andrée-Laure Herr; Julien Gautier; Sylvie Chabaud; Philippe Zrounba; David Perol; Jean-Yves Blay
Journal: Eur J Cancer Date: 2020-06-07 Impact factor: 9.162

5 in total

11 in total

1. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer.

Authors: Karen L Reckamp; Akil Merchant; Jane C Figueiredo; Noah M Merin; Omid Hamid; So Yung Choi; Tucker Lemos; Wendy Cozen; Nathalie Nguyen; Laurel J Finster; Joslyn Foley; Justin Darrah; Jun Gong; Ronald Paquette; Alain C Mita; Robert Vescio; Inderjit Mehmi; Reva Basho; Warren G Tourtellotte; Carissa A Huynh; Gil Y Melmed; Jonathan Braun; Dermot P B McGovern; Emebet Mengesha; Greg Botwin; John C Prostko; Edwin C Frias; James L Stewart; Sandy Joung; Jennifer Van Eyk; Joseph E Ebinger; Susan Cheng; Kimia Sobhani
Journal: Cancer Res Date: 2021-11-10 Impact factor: 13.312

2. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Authors: Stephen J Thomas; John L Perez; Stephen P Lockhart; Subramanian Hariharan; Nicholas Kitchin; Ruth Bailey; Katherine Liau; Eleni Lagkadinou; Özlem Türeci; Ugur Şahin; Xia Xu; Kenneth Koury; Samuel S Dychter; Claire Lu; Teresa C Gentile; William C Gruber
Journal: Vaccine Date: 2021-12-24 Impact factor: 3.641

Review 3. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.

Authors: C Corti; G Antonarelli; F Scotté; J P Spano; J Barrière; J M Michot; F André; G Curigliano
Journal: Ann Oncol Date: 2021-10-28 Impact factor: 32.976

4. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.

Authors: Andrea Becerril-Gaitan; Bryan F Vaca-Cartagena; Ana S Ferrigno; Fernanda Mesa-Chavez; Tonatiuh Barrientos-Gutiérrez; Marco Tagliamento; Matteo Lambertini; Cynthia Villarreal-Garza
Journal: Eur J Cancer Date: 2021-10-26 Impact factor: 9.162

Review 5. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.

Authors: Jérôme Barrière; Michel Carles; Clarisse Audigier-Valette; Daniel Re; Zoubir Adjtoutah; Barbara Seitz-Polski; Valérie Gounant; Diane Descamps; Gérard Zalcman
Journal: Eur J Cancer Date: 2021-12-16 Impact factor: 9.162

Reduced SARS-COV-2 infection and death after two doses of COViD-19 vaccines in a series of 1503 cancer patients.

1. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

2. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19.

3. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.

4. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

5. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.

1. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer.

2. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Review 3. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.

4. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.

Review 5. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.

6. COVID-19 Vaccination and Cancer, the Need for more Data

Review 7. COVID-19 vaccination in cancer patients: a narrative review.

8. COVID-19 vaccination in patients with cancer, a rapid review.

Review 9. Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.

10. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.